Clinical trials: Moderate and Severe Active Rheumatoid Arthritis
- Condition Moderate and Severe Active Rheumatoid Arthritis
- Funder type Industry (pharma, biotech, devices)
Rheumatoid Arthritis
ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)
This study evaluates ATI-450 plus MTX versus placebo plus MTX in participants with moderate to severe active RA who have had an inadequate response to MTX alone.
- Trial name
- NCT05279417
- Testing
- ATI-450 50 mg oral tablet BID, Methotrexate, ATI-450 20 mg oral tablet BID
- Where
- 50 sites in United States, Bulgaria and 2 more
- Volunteers
- 251 people
- Sponsor
- Aclaris Therapeutics, Inc.
Rheumatoid Arthritis
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
The primary objective of this study is to evaluate the efficacy of atacicept compared to placebo in the treatment of signs and symptoms in a subject population with active rheumatoid arthritis (RA), inadequate response to…
- Trial name
- AUGUST II (NCT00595413)
- Testing
- Atacicept: with loading dose, Atacicept, Adalimumab
- Where
- 2 sites in United States, Germany
- Volunteers
- 311 people
- Sponsor
- EMD Serono
Rheumatoid Arthritis(RA)
A Study Assessing the Efficacy and Safety of SM03 in Patients With Active Rheumatoid Arthritis Receiving MTX
To demonstrate that SM03 added to methotrexate (MTX) reduce signs and symptoms of rheumatoid arthritis (RA) in Chinese RA participants with an inadequate response to MTX.
- Trial name
- NCT04312815
- Testing
- SM03, MTX
- Where
- China
- Volunteers
- 510 people
- Sponsor
- SinoMab BioScience Ltd
Rheumatoid Arthritis
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
This study will investigate the efficacy of both low and high doses of methotrexate (MTX) in combination with open-label adalimumab (ADA) in patients who have had an inadequate response to high dose of MTX.
- Trial name
- MUSICA (NCT01185288)
- Testing
- Adalimumab, Methotrexate
- Where
- 49 sites in United States, Puerto Rico
- Volunteers
- 309 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis (RA)
Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study.
- Trial name
- NCT06982547
- Testing
- UTAA91 injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Rheumatoid Arthritis
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to determine whether baricitinib therapy alone is noninferior to methotrexate (MTX) therapy alone in the treatment of moderate to severe active rheumatoid arthritis (RA) in those who have had limited…
- Trial name
- RA-BEGIN (NCT01711359)
- Testing
- Baricitinib, Methotrexate, Folic Acid
- Where
- 154 sites in United States, Argentina and 17 more
- Volunteers
- 588 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)
The study objective of Period 1 of this study is to compare the safety and efficacy (signs and symptoms) of upadacitinib 30 mg once daily (QD) alone and upadacitinib 15 mg QD alone versus continuing MTX alone adults with…
- Trial name
- NCT02706951
- Testing
- Methotrexate, Upadacitinib
- Where
- 153 sites in United States, Argentina and 23 more
- Volunteers
- 648 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)
Participants suffering from active rheumatoid arthritis who had an inadequate response to methotrexate were evaluated for improvement of disease activity (efficacy) when taking GLPG0634 as monotherapy (3 different doses - 50…
- Trial name
- NCT01894516
- Testing
- GLPG0634
- Where
- 82 sites in United States, Argentina and 17 more
- Volunteers
- 287 people
- Sponsor
- Lakefront Biotherapeutics NV
Rheumatoid Arthritis
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
This 3 arm randomized open label study will evaluate the safety, tolerability and efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to or are unable to…
- Trial name
- NCT00891020
- Testing
- tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
- Where
- 227 sites in United States
- Volunteers
- 886 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.
- Trial name
- NCT04413617
- Testing
- PF-06650833, PF-06651600, Tofacitinib
- Where
- 144 sites in Bulgaria, Canada and 8 more
- Volunteers
- 460 people
- Sponsor
- Pfizer
Moderate to Severe Active Rheumatoid Arthritis
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
This is a multi-center, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of intravenous HS628 in combination with MTX versus Actemra in combination with MTX, in participants with moderate to…
- Trial name
- NCT06048224
- Testing
- HS628+MTX, Actemra +MTX
- Where
- China
- Volunteers
- 669 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Rheumatoid Arthrits
A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis
This study is to evaluate the efficacy and safety of different doses of proximod in moderate-to-severe active rheumatoid arthritis subjects with inadequate response or intolerance to bDMARDs and/or tsDMARDs
- Trial name
- NCT07856511
- Testing
- Proximod
- Volunteers
- 590 people
- Sponsor
- Jiankuan (Suzhou) Biotechnology Company Limited
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
This randomized, parallel-group, placebo-controlled, multicenter study will evaluate the reduction in disease activity and the safety of tocilizumab (RoActemra/Actemra) in combination with traditional disease-modifying…
- Trial name
- NCT01232569
- Testing
- Tocilizumab 162 mg
- Where
- 141 sites in United States, Argentina and 20 more
- Volunteers
- 656 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the joints, causing pain, swelling, stiffness, and loss of function.
- Trial name
- NCT07904754
- Testing
- ABBV-722, Upadacitinib
- Volunteers
- 250 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA
This is a Phase 2 study to investigate the safety, tolerability, PK, and PD of ATI-450 plus methotrexate versus methotrexate alone in patients with moderate to severe RA.
- Trial name
- NCT04247815
- Testing
- ATI-450, Methotrexate
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Aclaris Therapeutics, Inc.
Rheumatoid Arthritis
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
A phase 2a open-label study to evaluate the long-term safety and efficacy of ABX464 50mg as maintenance therapy in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT04049448
- Testing
- ABX464
- Where
- 14 sites in Belgium, France and 2 more
- Volunteers
- 40 people
- Sponsor
- Abivax S.A.
Rheumatoid Arthritis, Arthritis
A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoid arthritis.
- Conditions
- Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases
- Trial name
- RESOLUTION-1 (NCT05516758)
- Testing
- Peresolimab
- Where
- 131 sites in United States, Argentina and 9 more
- Volunteers
- 491 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis
This open-label, retrospective, observational study will evaluate the compliance to RoActemra/Actemra (tocilizumab) therapy in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT01375478
- Where
- 13 sites in Greece
- Volunteers
- 197 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
An observational study to describe the effectiveness, safety, and patient-reported outcomes in patients with moderate to severe active rheumatoid arthritis (RA) receiving filgotinib in real-world setting.
- Trial name
- FILOSOPHY (NCT04871919)
- Testing
- Filgotinib
- Where
- 89 sites in Belgium, Germany and 4 more
- Volunteers
- 1,304 people
- Sponsor
- Alfasigma S.p.A.
Rheumatoid Arthritis
Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis
This is a multicenter, randomized, double-blind, placebo and tocilizumab controlled phase II trial in RA patients to evaluate the initial efficacy, safety, pharmacokinetic, pharmacodynamic characteristics, and immunogenicity of…
- Trial name
- NCT05957107
- Testing
- Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
- Where
- 15 sites in China
- Volunteers
- 181 people
- Sponsor
- Beijing VDJBio Co., LTD.